Tita Patrizia, Ambrosio Maria Rosaria, Scollo Claudia, Carta Anna, Gangemi Pietro, Bondanelli Marta, Vigneri Riccardo, degli Uberti Ettore C, Pezzino Vincenzo
Divisione Clinicizzata di Endocrinologia, Ospedale Garibaldi, Catania, Italy.
Clin Endocrinol (Oxf). 2005 Aug;63(2):161-7. doi: 10.1111/j.1365-2265.2005.02316.x.
Acromegaly is a chronic disease caused by increased GH secretion and associated with a greater risk of developing both benign and malignant tumours. In the present study we evaluated the prevalence of thyroid disorders and thyroid malignancies in a series of acromegalic subjects.
We studied, retrospectively, a continuous series of 125 acromegalic patients referred to the Endocrinology Centres at the University Hospitals of Catania and Ferrara, Italy, over a 22-year period.
Diagnosis and management of acromegaly were based on standardized criteria. In all patients thyroid function and morphology were evaluated by serum free T4, free T3, TSH measurements and ultrasound scanning, respectively. Fine-needle aspiration biopsy (FNAB) was performed in all solid-mixed thyroid nodules of diameter greater than 1 cm. IGF-1 expression was assessed by semiquantitative immunohistochemical analysis in some patients with differentiated thyroid cancer.
Abnormal thyroid function was found in eight cases (6%). A diffuse or nodular goitre was present in 102 cases (82%). Thyroidectomy was performed in 17 patients. Histological examination revealed a differentiated thyroid cancer in seven of the patients. No significant association of thyroid cancer with GH or IGF-1 levels was found. Semiquantitative assessment of IGF-1 expression by immunohistochemistry revealed a more intense staining in thyroid cancer from acromegalic subjects than in papillary thyroid cancer from nonacromegalic subjects.
The frequency of thyroid disorders in our series of acromegalic subjects was similar to that previously observed in these patients. However, the prevalence of thyroid cancer was not only strikingly elevated (5.6%) in comparison to the estimated prevalence in the general population (0.093%), but it was even higher than that reported for acromegalic subjects. Sustained exposure to high serum IGF-1 levels is likely to play a role in the development of thyroid cancer in this disease. An additive role for the autocrine/paracrine action of locally produced IGF-1 is also possible. Our results suggest that thyroid function and morphology should be carefully monitored in all acromegalic patients.
肢端肥大症是一种由生长激素(GH)分泌增加引起的慢性疾病,与发生良性和恶性肿瘤的风险增加相关。在本研究中,我们评估了一系列肢端肥大症患者中甲状腺疾病和甲状腺恶性肿瘤的患病率。
我们回顾性研究了意大利卡塔尼亚和费拉拉大学医院内分泌中心在22年期间连续收治的125例肢端肥大症患者。
肢端肥大症的诊断和管理基于标准化标准。分别通过血清游离T4、游离T3、促甲状腺激素(TSH)测量和超声扫描评估所有患者的甲状腺功能和形态。对所有直径大于1 cm的实性混合性甲状腺结节进行细针穿刺活检(FNAB)。对一些分化型甲状腺癌患者通过半定量免疫组织化学分析评估胰岛素样生长因子-1(IGF-1)表达。
8例(6%)患者甲状腺功能异常。102例(82%)患者存在弥漫性或结节性甲状腺肿。17例患者接受了甲状腺切除术。组织学检查显示7例患者患有分化型甲状腺癌。未发现甲状腺癌与GH或IGF-1水平有显著关联。通过免疫组织化学对IGF-1表达进行半定量评估发现,肢端肥大症患者的甲状腺癌染色比非肢端肥大症患者的乳头状甲状腺癌更强烈。
我们系列肢端肥大症患者中甲状腺疾病的发生率与先前在这些患者中观察到的相似。然而,甲状腺癌的患病率不仅与一般人群的估计患病率(0.093%)相比显著升高(5.6%),甚至高于报道的肢端肥大症患者的患病率。持续暴露于高血清IGF-1水平可能在该疾病甲状腺癌的发生中起作用。局部产生的IGF-1的自分泌/旁分泌作用也可能起累加作用。我们的结果表明,所有肢端肥大症患者都应仔细监测甲状腺功能和形态。